|
|
 Previous Article | Table of Contents | Next Article 
A canine model of hemophilic (factor VIII:C deficiency) bleeding
AR Giles, S Tinlin and R Greenwood
A model of bleeding due to clotting factor deficiency has been developed in
dogs. Normal and hemophilic (factor VIII:C deficient) animals were used.
Bleeding was induced in lightly anesthetized animals by severing the apex
of the nail cuticle using a guillotine device. In normal animals, bleeding
usually ceased spontaneously after 2-8 min. In contrast, in hemophilic
animals, bleeding continued for up to 20 min and necessitated either
cauterization or the application of topical thrombin to achieve hemostasis.
Pretreatment of the hemophilic animals with canine cryoprecipitate
corrected the cuticle bleeding time to within the range noted for normal
animals. The method is simple and reproducible and has the advantage that a
number of observations can be made sequentially on the same animal.
Rebleeding of the cauterized cuticle of the hemophilic animals did not
usually occur. This model has considerable potential for the preclinical
testing of products considered to bypass or replace factor VIII:C in
patients with acquired inhibitors of factor VIII:C and may be adapted to
the study of other mechanisms involved in normal and abnormal hemostasis.
Volume 60,
Issue 3,
pp. 727-730,
09/01/1982
Copyright © 1982 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Prasad, D. Lillicrap, A. Labelle, S. Knappe, T. Keller, E. Burnett, S. Powell, and K. W. Johnson
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A
Blood,
January 15, 2008;
111(2):
672 - 679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jiang, D. Lillicrap, S. Patarroyo-White, T. Liu, X. Qian, C. D. Scallan, S. Powell, T. Keller, M. McMurray, A. Labelle, et al.
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
Blood,
July 1, 2006;
108(1):
107 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Brown, C. X. Shi, S. Powell, D. Hurlbut, F. L. Graham, and D. Lillicrap
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A
Blood,
February 1, 2004;
103(3):
804 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Scallan, D. Lillicrap, H. Jiang, X. Qian, S. L. Patarroyo-White, A. E. Parker, T. Liu, J. Vargas, D. Nagy, S. K. Powell, et al.
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector
Blood,
September 15, 2003;
102(6):
2031 - 2037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C. Wong, E. J. Crain, C. A. Watson, A. M. Zaspel, M. R. Wright, P. Y. Lam, D. J. P. Pinto, R. R. Wexler, and R. M. Knabb
Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits
J. Pharmacol. Exp. Ther.,
December 1, 2002;
303(3):
993 - 1000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Lozier, A. Dutra, E. Pak, N. Zhou, Z. Zheng, T. C. Nichols, D. A. Bellinger, M. Read, and R. A. Morgan
The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion
PNAS,
October 1, 2002;
99(20):
12991 - 12996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Refino, S. Jeet, L. DeGuzman, S. Bunting, and D. Kirchhofer
A Human Antibody That Inhibits Factor IX/IXa Function Potently Inhibits Arterial Thrombosis Without Increasing Bleeding
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2002;
22(3):
517 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gallo-Penn, P. S. Shirley, J. L. Andrews, S. Tinlin, S. Webster, C. Cameron, C. Hough, C. Notley, D. Lillicrap, M. Kaleko, et al.
Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs
Blood,
January 1, 2001;
97(1):
107 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Connelly, J. L. Andrews, A. M. Gallo, D. B. Kayda, J. Qian, L. Hoyer, M. J. Kadan, M. I. Gorziglia, B. C. Trapnell, A. McClelland, et al.
Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy
Blood,
May 1, 1998;
91(9):
3273 - 3281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Turecek, H. Gritsch, L. Pichler, W. Auer, B. Fischer, A. Mitterer, W. Mundt, U. Schlokat, F. Dorner, H. J. M. Brinkman, et al.
In Vivo Characterization of Recombinant von Willebrand Factor in Dogs With von Willebrand Disease
Blood,
November 1, 1997;
90(9):
3555 - 3567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
